Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Por:
Scher JU, Nayak RR, Ubeda C, Turnbaugh PJ and Abramson SB
Publicada:
1 may 2020
Ahead of Print:
1 mar 2020
Categoría:
Rheumatology
Resumen:
In the past three decades, extraordinary advances have been made in the understanding of the pathogenesis of, and treatment options for, inflammatory arthritides, including rheumatoid arthritis and spondyloarthritis. The use of methotrexate and subsequently biologic therapies (such as TNF inhibitors, among others) and oral small molecules have substantially improved clinical outcomes for many patients with inflammatory arthritis; for others, however, these agents do not substantially improve their symptoms. The emerging field of pharmacomicrobiomics, which investigates the effect of variations within the human gut microbiome on drugs, has already provided important insights into these therapeutics. Pharmacomicrobiomic studies have demonstrated that human gut microorganisms and their enzymatic products can affect the bioavailability, clinical efficacy and toxicity of a wide array of drugs through direct and indirect mechanisms. This discipline promises to facilitate the advent of microbiome-based precision medicine approaches in inflammatory arthritis, including strategies for predicting response to treatment and for modulating the microbiome to improve response to therapy or reduce drug toxicity.
Pharmacomicrobiomics studies investigating the effect of variations within the human gut microbiome on drugs have provided insights into therapeutics used for inflammatory arthritis, which could facilitate microbiome-based precision medicine approaches in rheumatology.
Filiaciones:
Scher JU:
Department of Medicine, Division of Rheumatology, New York University Langone Health, New York, NY, USA.
Nayak RR:
Rheumatology Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
Department of Microbiology & Immunology, University of California, San Francisco, CA, USA
:
Área de Genómica y Salud_Centro Superior de Investigacion en Salud Publica - FISABIO, Valencia, Spain
CIBER en Epidemiología y Salud Pública, Madrid, Spain
Turnbaugh PJ:
Department of Microbiology & Immunology, University of California, San Francisco, CA, USA
Chan Zuckerberg Biohub, San Francisco, CA, USA
Abramson SB:
Department of Medicine, Division of Rheumatology, New York University Langone Health, New York, NY, USA
|